Galaxia

Quick links to important sections

Galaxia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galaxia

What is Galaxia? An Overview of Latanoprost

Property Description
Active Ingredient Latanoprost
Form Ophthalmic Solution (Eye drops)
Pharmacological Class Prostaglandin F2alpha Analog
General Purpose Reduction of Elevated Intraocular Pressure (IOP)
Origin Synthetic Prodrug

What Type of Medicine is Galaxia?

Galaxia is a prescription medication classified as a targeted antiglaucoma preparation, formulated as a sterile, isotonic, buffered aqueous solution for topical ocular administration as eye drops. Its classification under the pharmacological class of prostaglandin F2alpha analogs defines its function as a prostanoid FP receptor agonist. This means the drug is designed to work specifically by mimicking a natural body compound to regulate pressure within the eye. The medication is clinically recognized for its efficacy and is frequently considered a first-line treatment option for managing elevated pressure.


Composition and Purpose: Latanoprost and IOP Reduction

The single active ingredient in Galaxia is Latanoprost, a synthetic chemical entity and an isopropyl ester prodrug. The prodrug nature is crucial: Latanoprost is inactive when applied, but it is swiftly activated through hydrolysis into latanoprost acid upon absorption by the eye. The core therapeutic purpose of Galaxia is the sustained reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost is recognized as effective in lowering IOP compared to placebo. The drug achieves this by enhancing the eye's natural fluid drainage, specifically by increasing the uveoscleral outflow of the aqueous humor.

What side effects are possible with Galaxia?

Galaxia: Possible Side Effects and Safety Information

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), require the most serious safety information for Galaxia to be presented in a Boxed Warning. This warning highlights the potential for serious and life-threatening adverse reactions.

Serious and Clinically Significant Risks

The Boxed Warning specifically alerts to an increased risk of serious heart-related events (including myocardial infarction and stroke), malignancies (such as lymphoma and lung cancer), thrombosis (deep vein thrombosis and pulmonary embolism), and death. The risk of these events is generally considered higher in patients who are current or past smokers, or those with existing cardiovascular risk factors. Due to these potential serious risks, official labeling may reserve use of this medicine for patients who have had an inadequate response to one or more TNF blockers.

Adverse Reaction Categories

Adverse reactions documented in official sources span multiple System-Organ Classes. These often include: Infections and infestations, Blood and lymphatic system disorders, Gastrointestinal disorders (e.g., diarrhea, abdominal pain), Nervous system disorders (e.g., headache, dizziness), and Skin and subcutaneous tissue disorders. These effects are categorized by frequency, typically using the MedDRA convention (e.g., Very common geq1/10, Common geq1/100 to <1/10, etc.) as defined in regulatory texts.

High-Level Safety Monitoring Notes

  • Regulatory Basis: The safety profile is defined by governmental authority assessments, such as the FDA.
  • Context-of-Use: Safety information mandates caution, particularly in high-risk groups, and notes that the product may be reserved for use after failure with other specific treatment classes.

The overall safety profile is characterized by the presence of severe, potentially fatal risks, which necessitate a high level of caution and careful patient selection before and during use, as stipulated in the official prescribing information.

Overdose and Emergency Response

The regulatory documentation for Galaxia defines overdose scenarios based on exposure route and documented clinical manifestations.

Documented Overdose Manifestations Topical administration of the ophthalmic solution in amounts exceeding the prescribed dose is officially characterized by local ocular effects. The documented manifestations are ocular irritation, alongside the occurrence of conjunctival hyperemia, characterized by visible redness of the conjunctiva, and episcleral hyperemia.

Severity and Systemic Risk Systemic danger is not anticipated following a topical overdose. Regulatory information indicates that the overdose is not expected to result in dangerous patient outcomes, a finding supported by studies showing that even high systemic concentrations of the active ingredient did not cause severe adverse effects. No specific antidote for Latanoprost is known or documented.

Emergency Action Required The regulator-mandated condition for seeking urgent medical attention is the accidental oral ingestion of the ophthalmic solution. In this specific event, it is required to seek immediate medical attention or contact an emergency poison control resource immediately. Treatment for any overdose situation is defined as consisting of necessary symptomatic and supportive measures.

Therapeutic Uses of Galaxia

What Galaxia Treats: Main Uses and Benefits

The therapeutic approach is generally considered relevant when supportive symptom management is appropriate for symptoms that create noticeable physiological strain. The core medication category is used to address several forms of pain linked to nerve damage.

Galaxia is commonly used to help with symptomatic relief in clinical scenarios involving chronic nerve pain, such as Diabetic Peripheral Neuropathy, post-herpetic neuralgia, or fibromyalgia. It is applied in addressing symptoms related to physical discomfort caused by nerve irritation, including persistent burning, shooting, or tingling sensations. The medication is applicable in conditions characterized by periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

It is relevant for easing symptom clusters that may become intense or disruptive and may help patients cope more steadily with symptom fluctuations.

“It provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relevant for Managing Neuropathic Pain Symptoms

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

The decision to use Galaxia (nitrous oxide for medical purposes) must be made by a qualified healthcare professional, who will determine its appropriateness based on the patient's full medical history.

Appropriate Use

Galaxia is widely used as an inhaled analgesic and anxiolytic agent. It is safe for most people, including children and adults, when administered in a supervised clinical setting, such as for dental procedures, during labor, or for short-term pain relief in emergency or minor surgical settings. Its fast onset and quick reversal of effects make it suitable for procedures where the patient needs to recover quickly.


Contraindications and Precautions

Galaxia is contraindicated (should not be used) in patients with certain conditions where the expansion of gas trapped within a body cavity could be dangerous. These include, but are not limited to:

  • Pneumothorax (collapsed lung) or air embolism.
  • Recent intraocular gas injection (e.g., following retinal surgery).
  • Severe head injury with impaired consciousness.
  • Significant middle ear blockage or air trapping in the sinuses.

Use requires caution and may be unsuitable for individuals with a history of Vitamin B12 deficiency, certain chronic respiratory diseases (like severe COPD), or a history of severe psychiatric conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Galaxia (Latanoprost) based on localized ocular constraints and the lack of systemic pharmacokinetic data, rather than broad metabolic pathways.

Official Interaction Restrictions

Category Documented Interaction Pattern
Pharmacodynamic Restriction Co-administration with other ophthalmic prostaglandin analogs (e.g., bimatoprost, travoprost) is not recommended. This official restriction exists because the combination risks a paradoxical elevation of intraocular pressure (IOP) or a reduction of the IOP-lowering effect.
Physicochemical Constraint Other ophthalmic solutions containing the preservative thimerosal must be administered at least five (5) minutes apart from Galaxia. This mandatory time separation prevents the officially described risk of in vitro precipitation of the active substance.

Systemic and Other Interaction Data

Category Documentation Status
Systemic Pharmacokinetic Data Not available. Regulatory authorities explicitly state that specific drug-drug interaction studies concerning systemic metabolism (e.g., CYP enzymes, transporters) have not been conducted, and definitive data are not available.
Food, Alcohol, Supplements Not Documented. Official regulatory labeling contains no specific statements regarding interactions with food, alcohol, or herbal products.

The official profile is characterized by restrictions focused on local administration. The risk associated with combining it with other prostaglandin analogs constitutes a significant regulatory constraint on use.

Mechanism of Action

Molecular Activation and FP Receptor Agonism

Galaxia's action is defined by a two-step process that modifies the eye's internal fluid dynamics through structural changes, independent of mechanisms that reduce fluid production or immediate smooth muscle contraction. The mechanism initiates when the inactive Latanoprost prodrug is chemically converted to its active metabolite, latanoprost acid, within the eye. This active acid then acts as a selective agonist (activator) of the Prostanoid FP Receptor found on the ciliary muscle cells. This targeted molecular interaction initiates the downstream mechanistic cascade that modulates pressure.

️ Tissue Remodeling and Enhanced Uveoscleral Outflow

Activation of the FP receptor promotes the release and activity of specific Matrix Metalloproteinases (MMPs), enzymes that mediate the remodeling of the extracellular matrix (ECM) within the ciliary muscle and uveoscleral tract. This enzymatic remodeling increases the porosity and spacing of the tissue, thereby reducing the resistance to fluid flow and enhancing the drainage of aqueous humor through the uveoscleral outflow pathway. This enhanced drainage is the direct physiological action that results in the reduction of intraocular pressure (IOP).

Dosage and Administration Information

Official Administration Guidelines

Galaxia is a drug administered only to adults as an intravenous infusion once weekly. The dosage is strictly determined by the patient's weight at 60 mg/kg body weight. The administration must be conducted by a healthcare professional or by a patient/caregiver after receiving detailed, appropriate training.

Preparation and Procedure

Before administration, use aseptic technique and allow the product to reach room temperature. Inspect the solution; it should appear clear and colorless to yellow-green, and must be discarded if cloudy. The product must be administered alone and should not be mixed with any other agents or diluting solutions. Infusion must be completed within three hours of opening the vials.

The entire infusion procedure requires the use of a 5 micron in-line filter. The product should be infused at a rate that does not exceed 0.2 mL/kg body weight per minute. The rate may be reduced or the infusion interrupted if the patient experiences adverse events, and then resumed at a tolerated rate. After administration, all open vials and unused solution must be discarded.

Missed Dose

Specific regulatory instructions for a missed dose of Galaxia are not universally documented across all official summaries, meaning full prescribing information must be consulted to determine the precise procedural steps for rescheduling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Galaxia (Latanoprost)


Evidence for Use in Primary Open-Angle Glaucoma and Ocular Hypertension

Galaxia (latanoprost) was studied in research exploring elevated Intraocular Pressure (IOP), which is the pressure inside the eye. The research relies on Randomized Controlled Trials (RCTs) and large-scale meta-analyses. These studies compared latanoprost against an inactive substance (placebo) or against other eye drops used to address IOP. The main aim of this research was to monitor the absolute and relative change in pressure measured in the eyes of adults diagnosed with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Findings from these controlled trials and systematic reviews reported measurements of IOP, with studies reporting patterns related to lower mean IOP levels recorded compared to baseline. The evidence contributes to understanding how IOP levels evolved in the observed populations during the study period.

  • Study Focus: Comparing Latanoprost to Placebo and Other Agents

In the research, latanoprost was evaluated in direct comparison to an inactive solution (placebo) and was studied for its IOP measurements against other active comparator agents, such as beta-blockers (like timolol) or other prostaglandin-class drugs. The comparisons were conducted to observe the pressure measurements recorded across different therapeutic approaches. The reported differences in measured IOP was observed to vary in some studies.


Research on Elevated IOP in Chronic Angle-Closure Glaucoma

Research has explored latanoprost in specific contexts, including elevated IOP in eyes with Chronic Angle-Closure Glaucoma (CACG). This generally involves adult patients with elevated pressure following initial procedures like iridotomy. The evidence base for this context is still emerging, with fewer dedicated, large-scale trials available compared to POAG/OHT. Because sample sizes were modest and the patient presentation can vary significantly, the evidence quality varies across studies, meaning certainty remains low.


Research Gaps and Uncertainty

Despite the significant volume of research for Primary Open-Angle Glaucoma, evidence highlights what is known—and what is still uncertain.

  • Follow-up durations were limited in many pivotal trials regarding functional outcomes, meaning the long-term impact on visual field health is not fully established by the controlled research.
  • Data for certain groups remain insufficient, especially for children.
  • Subgroup findings are uncertain when comparing latanoprost to its pharmaceutical analogs, where studies report differences in IOP measurements. The clinical significance of these differences is not fully established by the existing evidence base.

Key Studies & References

  1. Glaucoma: diagnosis and management (National Institute for Health and Care Excellence (NICE) Guideline NG81)

Frequently Asked Questions (FAQ)

Common questions about Galaxia (FAQ)

Q: What happens if a dose of Galaxia is missed?

A: Official instructions typically state that a missed dose is generally skipped, and the patient returns to the regular scheduled administration. Regulatory documents generally caution against administering more than one dose to compensate for a missed one.

Q: How quickly should someone expect Galaxia to start working?

A: Regulatory documents indicate that the process of reducing pressure inside the eye usually begins approximately three to four hours after the first administration. The maximum pressure-lowering effect has typically been measured eight to twelve hours after administration in studies.

Q: Can Galaxia be used by teenagers or children?

A: Official documentation often notes that the safety and effectiveness of Galaxia have not been fully established in the pediatric population (children and adolescents). Official guidance means that the use of this medicine is primarily directed toward adults.

Q: Do studies mention a typical time frame for seeing the full effects of Galaxia?

A: Studies and regulatory information report that the maximum reduction of intraocular pressure, which signifies the full effect, is typically measured eight to twelve hours following the evening administration.

Q: Are there any known interactions between Galaxia and herbal supplements like St. John's Wort?

A: Official regulatory documents do not contain specific statements regarding interactions with food, alcohol, or common herbal supplements. It is important to review the official interaction warnings, which focus on co-administered eye drops.

Q: Can Galaxia be taken with daily vitamins or supplements?

A: The official regulatory labeling does not provide specific data or warnings concerning interactions with daily vitamins or general nutritional supplements. The official interaction profile is primarily characterized by warnings related to other eye medications.

Q: How long does Galaxia stay in the body after the last dose?

A: According to the official pharmacokinetics data, the active substance of Galaxia is rapidly processed and eliminated from the systemic circulation. Its half-life in the blood plasma is reported to be approximately 17 minutes.

Q: Is Galaxia associated with any specific warnings about kidney or liver function?

A: While the medicine is metabolized by the liver, official regulatory documentation typically does not contain specific contraindications or major warnings concerning pre-existing impaired kidney or liver function.

Q: Can I take Galaxia if I am also taking an antidepressant?

A: Regulatory authorities have generally not conducted specific drug-drug interaction studies concerning systemic medications. Definitive data on systemic drug-drug interactions, such as with antidepressants, are often noted as not widely available in the official prescribing information.

Q: Are the side effects of Galaxia permanent?

A: Some documented side effects, most notably the increased brown pigmentation of the iris, are described as being likely permanent. However, changes to the eyelid skin color or increased eyelash growth have been reported to be reversible in some patients after treatment is stopped.

Q: What happens if someone accidentally takes too much Galaxia?

A: Official documents concerning overdosage suggest that treatment focuses on managing symptoms. If eye irritation is present, official guidance notes that the eye may be rinsed with water.

Q: Does Galaxia require regular blood tests or monitoring?

A: Official patient counseling information emphasizes the need for regular visits to a healthcare professional to monitor the pressure inside the eye and check for unwanted effects. Specific, routine systemic blood tests are not typically mandated in the official labeling.

Q: Is there a preferred time of day to take Galaxia?

A: Official prescribing information for Galaxia usually specifies that the once-daily administration is intended to be in the evening.

Q: Is Galaxia considered a long-term medication?

A: Galaxia is indicated for chronic conditions such as open-angle glaucoma and ocular hypertension. Clinical trials and safety follow-ups cover extended use periods, which is consistent with its intended role as a continuous treatment.

Q: What if I feel like Galaxia isn't working after a few days?

A: The maximum pressure-lowering effect is reached 8 to 12 hours after administration. Official documents state that the full benefit of pressure reduction may not be fully apparent until after a period of regular use.

Q: Is it normal to feel a little dizzy when first starting Galaxia?

A: Dizziness is listed among the reported adverse reactions in official regulatory documents, though it is typically categorized as uncommon. Official sources do not use the term 'normal' when describing how the body may react to a new medicine.

Q: Do older adults need any special considerations when using Galaxia?

A: Studies specifically addressing use in older adults have not demonstrated geriatric-specific problems that would generally limit the usefulness of this medicine compared to younger adults.

Q: Is it safe to drive or operate machinery while taking Galaxia?

A: Regulatory warnings advise that if a patient experiences blurred vision or other vision disturbances after administration, they should not drive or operate machinery until the problems have resolved.

Q: What is the risk of dependence or addiction with Galaxia?

A: Official prescribing information generally contains an explicit statement that there is no known evidence or information suggesting a potential for abuse or dependence with latanoprost.

Q: Can Galaxia be stopped suddenly, or does it need to be tapered off?

A: Stopping the medicine typically causes the intraocular pressure to return to pre-treatment levels within a few weeks. The decision to discontinue use or change treatment requires consultation with a qualified healthcare professional.

Q: How does Galaxia affect sleep patterns?

A: While regulatory documents list some central nervous system side effects such as headache, there is no specific adverse reaction category for sleep pattern changes or insomnia among the most commonly reported effects.

Q: Is Galaxia safe for people with certain chronic health conditions?

A: Official documents list certain existing chronic conditions as precautions or contraindications for use. Examples include having a history of intraocular inflammation (such as iritis or uveitis) or severe uncontrolled asthma.

Q: What is the difference between Galaxia and generic versions, if available?

A: Regulatory bodies require generic versions to be identical to the brand-name drug in terms of active ingredient strength and dosage form. Differences may occasionally exist in the inactive ingredients or the physical design of the dispenser.

Q: Does the effectiveness of Galaxia decrease over time?

A: Regulatory reviews of clinical trials have reported sustained intraocular pressure reduction over the period studied (e.g., up to 12 months). It is noted that using the eye drops more frequently than recommended may reduce the pressure-lowering effect.

Q: Are there any long-term health risks associated with taking Galaxia for many years?

A: Long-term effects have been studied; while the increased iris pigmentation is generally considered permanent, the effects are mostly confined to the eye. Clinical evidence suggests the drug's systemic clearance is rapid.

Q: What is the significance of the research phase or trial results for Galaxia?

A: The research evidence, primarily randomized controlled trials, established that Galaxia consistently reduced Intraocular Pressure (IOP) compared to placebo. This evidence supported its regulatory approval and classification as a recognized treatment for its indications.

Q: Is Galaxia a new drug or has it been around for a long time?

A: Galaxia (latanoprost) has been available for an extended period, having first received approval for marketing from regulatory agencies such as the U.S. FDA in 1996.

Q: Do research summaries indicate who responds best to Galaxia?

A: The clinical evidence indicates effectiveness across the studied adult population with its approved conditions. Subgroup findings comparing it to other similar treatments are reported as having some uncertainty in efficacy measurements.

Q: Is Galaxia available over the counter in some countries?

A: In many countries with advanced regulatory systems, Galaxia (latanoprost) is classified as a prescription medicine. This means it can only be obtained with a valid prescription from a qualified healthcare professional.

How should Galaxia be stored and disposed of?

Storage and Disposal Conditions for Galaxia

Galaxia (Latanoprost Ophthalmic Solution) requires specific temperature and handling controls to maintain its efficacy and sterility, as mandated by regulatory labeling.


Storage Requirements

Condition Requirement
Unopened Bottle Must be stored under refrigeration between mathbf2^circC and mathbf8^circC (mathbf36^circF to mathbf46^circF). Do not freeze.
Opened Bottle May be stored at room temperature up to mathbf25^circC (mathbf77^circF).
Stability Limit Must be discarded four to six weeks after opening.
Protection Store in the original outer carton to protect from light.

Disposal and Safety

The medicine must be kept out of the sight and reach of children at all times. Unused or expired Galaxia must be disposed of according to the instructions of a healthcare professional or local environmental regulations; the solution should not be thrown into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Galaxia found in:

A-Z Index: